• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Evidence-based Practice
      Center for Medical Technology Assessment
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [20545 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Health Technology Wales (HTW) Extreme hypofractionated radiotherapy (EHFRT) for localised prostate cancer
2022     Health Technology Wales (HTW) Convalescent plasma therapy for the treatment of COVID-19
2022     Austrian Institute for Health Technology Assessment (AIHTA) Lower esophageal sphincter devices for laparoscopic surgery in patients with gastroesophageal reflux disease (GERD)
2022     Austrian Institute for Health Technology Assessment (AIHTA) Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer
2022     Austrian Institute for Health Technology Assessment (AIHTA) His-bundle-pacing for patients requiring a permanent pacemaker or cardiac resynchronisation
2022     Austrian Institute for Health Technology Assessment (AIHTA) Microwave ablation for liver tumours
2022     Austrian Institute for Health Technology Assessment (AIHTA) Hepatic and portal vein embolisation prior to major hepatectomy
2022     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous transvascular implantation of a coronary sinus reducing stent. Update 2022
2022     Austrian Institute for Health Technology Assessment (AIHTA) Subcutaneous implantable cardioverter-defibrillator (S-ICD). Update 2022
2022     Austrian Institute for Health Technology Assessment (AIHTA) Upper airway stimulation for moderate-to-severe sleep apnoea. Update 2022
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at workplaces in controlling the spread of COVID-19]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at commerce in controlling the spread of COVID-19]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous coronary interventions (PCI) for chronic total occlusion (CTO). Update 2022
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Portable home hemodialysis systems]
2022     Center for Drug Evaluation (CDE) The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: issues pertaining to the implementation of a clinical decision support system for diagnostic test ordering]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: service trajectories and services for at risk or neglected children and their families]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the optimal usage guide on sexually transmitted and blood borne infections – confirmed Mycoplasma genitalium infection]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: Hereditary Cardiovascular diseases NGS Panel - Evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022     NIHR Health Services and Delivery Research programme Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022     NIHR Health Technology Assessment programme Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022     Institute for Clinical and Economic Review (ICER) Tirzepatide for type 2 diabetes
2022     Institute for Clinical and Economic Review (ICER) Special assessment of outpatient treatments for COVID-19
2022     Institute for Clinical and Economic Review (ICER) Betibeglogene autotemcel for beta thalassemia: effectiveness and value
2022     Health Information and Quality Authority (HIQA) Health technology assessment of metabolic surgery for the treatment of comorbid type 2 diabetes and obesity
2022     Agency for Care Effectiveness (ACE) Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for chronic lymphocytic leukaemia
2022     Agency for Care Effectiveness (ACE) Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
2022     Agency for Care Effectiveness (ACE) Daratumumab-based regimens for newly diagnosed multiple myeloma
2022     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2022     Agency for Care Effectiveness (ACE) Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating early or advanced HER2-positive breast cancer
2022     Agency for Care Effectiveness (ACE) Ruxolitinib for treating polycythaemia vera
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating advanced urothelial carcinoma
2022     Agency for Care Effectiveness (ACE) Brentuximab vedotin for treating T-cell lymphoma
2022     Agency for Care Effectiveness (ACE) Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2022     Norwegian Institute of Public Health (NIPH) [Overdose warning systems: a single technology assessment - mapping]
2022     Norwegian Institute of Public Health (NIPH) [Transcranial direct current stimulation for depression and aphasia. A health technology assessment]
2022     Ontario Health Mechanical thrombectomy for acute and subacute blocked arteries and veins in the lower limbs
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy of psychosocial interventions for the prevention and treatment of common mental disorders and symptoms]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Evaluation of Fibryga (human fibrinogen concentrate) – acquired fibrinogen deficiency]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: molecular profiling of adult solid tumors - Focus Panel (Illumina) – 52 somatic biomarkers analysis]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: helicopter emergency medical services (HEMS) - needs analysis and clientele identification]
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022     Agency for Care Effectiveness (ACE) Bevacizumab biosimilar for treating different types of cancers
2022     Agency for Care Effectiveness (ACE) PARP inhibitors and bevacizumab for treating advanced ovarian cancer
2022     Agency for Care Effectiveness (ACE) Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
2022     Agency for Care Effectiveness (ACE) Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
2022     Agency for Care Effectiveness (ACE) Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2022     Agency for Care Effectiveness (ACE) High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
2022     Agency for Care Effectiveness (ACE) Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer
2022     Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated multiple myeloma
2022     Agency for Care Effectiveness (ACE) Immune checkpoint inhibitors and BRAK/MEK inhibitors for treating advanced malignant melanoma
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating differentiated thyroid cancer
2022     Agency for Care Effectiveness (ACE) Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia
2022     Agency for Care Effectiveness (ACE) Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
2022     Agency for Care Effectiveness (ACE) Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
2022     Agency for Care Effectiveness (ACE) Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for prostate cancer
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating ALK mutation-positive advanced non-small-cell lung cancer
2022     Agency for Care Effectiveness (ACE) Update of MOH list of subsidised drugs to include treatments for various cancer conditions
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced gastric cancer
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors, immune checkpoint inhibitors and everolimus for treating advanced renal cell cancer
2022     Agency for Care Effectiveness (ACE) Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for acute lymphoblastic leukaemia
2022     Agency for Care Effectiveness (ACE) Disease-modifying therapies for treating multiple sclerosis
2022     Agency for Care Effectiveness (ACE) Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
2022     Agency for Care Effectiveness (ACE) Infliximab biosimilar for treating inflammatory conditions
2022     Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
2022     Agency for Care Effectiveness (ACE) Denosumab for treating osteoporosis and glucocorticoid-associated bone loss
2022     Agency for Care Effectiveness (ACE) Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with single sided deafness
2022     Agency for Care Effectiveness (ACE) Active middle ear implants for patients with hearing loss
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with conductive or mixed hearing loss
2022     Agency for Care Effectiveness (ACE) Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes
2022     Agency for Care Effectiveness (ACE) Percutaneous vertebral augmentation systems for treating patients with vertebral compression fractures
2022     Agency for Care Effectiveness (ACE) Bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears
2022     Agency for Care Effectiveness (ACE) Overview of clinical applications of telemedicine
2022     Agency for Care Effectiveness (ACE) 3D printing and its clinical applications
2022     Agency for Care Effectiveness (ACE) Artificial intelligence and its clinical applications
2022     Agency for Care Effectiveness (ACE) The PrecivityAD test for the prognosis of Alzheimer's disease
2022     Agency for Care Effectiveness (ACE) Caption guidance to guide image acquisition in point-of-care echocardiography for patients with cardiovascular disease
2022     Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022     Agency for Care Effectiveness (ACE) Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022     Scottish Health Technologies Group (SHTG) Chest wall bracing for children and young people with pectus carinatum
2022     Scottish Health Technologies Group (SHTG) Minuteful Kidney for home testing of albumin-to-creatine ratio (ACR)
2022     NIHR Health Services and Delivery Research programme Safety of disinvestment in mid- to late-term follow-up post primary hip and knee replacement: the UK SAFE evidence synthesis and recommendations
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 1 - overview of heart and lung transplantation in Québec]